- Severe disorders with devastating and life-threatening medical consequences
- Disorders with ineffective, or no treatment options
- Disorders that are ultra-rare and affect very small numbers of patients
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.
Alexion Pharma (ALXN) stock coverage was started at FBR Capital on Thursday.